### 1 Combining a prioritization strategy and functional studies nominates 5'UTR

### 2 variants underlying inherited retinal disease

- 3 Alfredo Dueñas Rey<sup>1,2</sup>, Marta del Pozo Valero<sup>1,2,3,\*</sup>, Manon Bouckaert<sup>1,2\*</sup>, Filip Van Den Broeck<sup>4,5</sup>,
- 4 Malena Daich Varela<sup>6,7</sup>, Mattias Van Heetvelde<sup>1,2</sup>, Marieke De Bruyne<sup>1,2</sup>, Stijn Van de Sompele<sup>1,2</sup>,
- 5 Miriam Bauwens<sup>1,2</sup>, Jamie Ellingford<sup>8,9,10</sup>, Hanne Lenaerts<sup>1,2</sup>, Quinten Mahieu<sup>1,2</sup>, Dragana Josifova<sup>11</sup>,
- 6 Genomics England Research Consortium<sup>10</sup>, Carlo Rivolta<sup>12,13,14</sup>, Andrew Webster<sup>6,7</sup>, Gavin Arno<sup>6,7</sup>,
- 7 Carmen Ayuso<sup>3,15</sup>, Julie De Zaeytijd<sup>4,5</sup>, Bart P. Leroy<sup>1,4,5,16</sup>, Elfride De Baere<sup>1,2</sup>, Frauke Coppieters<sup>1,2,17</sup>
- 8 1. Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
- 9 2. Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
- 10 3. Department of Genetics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, University
- 11 Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM).
- 12 4. Department of Ophthalmology, Ghent University Hospital, Ghent, Belgium.
- 13 5. Department of Head & Skin, Ghent University, Ghent, Belgium.
- 14 6. UCL Institute of Ophthalmology, London, UK.
- 15 7. Moorfields Eye Hospital, London, UK.
- 16 8. Division of Evolution, Infection and Genomic Sciences, School of Biological Sciences, Faculty of
- 17 Biology, Medicines and Health, University of Manchester, Manchester, UK.
- 18 9. Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS
- 19 Foundation Trust, Manchester, UK.
- 20 10. Genomics England, London, UK.
- 21 11. Clinical Genetics Department, Guy's Hospital, London, UK.
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 12. Department of Ophthalmology, University of Basel, Basel, Switzerland.

- 23 13. Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.
- 24 14. Department of Genetics and Genome Biology, University of Leicester, Leicester, UK.
- 25 15. Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III,
- 26 Madrid, Spain.
- 27 16. Division of Ophthalmology & Center for Cellular & Molecular Therapeutics, Children's Hospital of
- 28 Philadelphia, Philadelphia, PA, USA.
- 29 17. Department of Pharmaceutics, Ghent University, Ghent, Belgium.

- 31 \* Shared second co-authors
- 32 Corresponding author: Frauke Coppieters (frauke.coppieters@ugent.be)
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 40
- 41

### 42 Abstract

Background | 5' untranslated regions (5'UTRs) are essential modulators of protein translation.
Predicting the impact of 5'UTR variants is challenging and typically not performed in routine
diagnostics. Here, we present a combined approach of a comprehensive prioritization strategy
and subsequent functional assays to evaluate 5'UTR variation in two large cohorts of patients
with inherited retinal diseases (IRDs).

48 Methods | We performed an isoform-level re-analysis of retinal RNA-seq data to identify the protein-coding transcripts of 378 IRD genes with highest expression in retina. We evaluated 49 50 the coverage of these 5'UTRs by different whole exome sequencing (WES) capture kits. The selected 5'UTRs were analyzed in whole genome sequencing (WGS) and WES data from IRD 51 sub-cohorts from the 100,000 Genomes Project (n = 2,417 WGS) and an in-house database (n 52 53 = 1,682 WES), respectively. Identified variants were annotated for 5'UTR-relevant features and 54 classified into 7 distinct categories based on their predicted functional consequence. We 55 developed a variant prioritization strategy by integrating population frequency, specific criteria for each category, and family and phenotypic data. A selection of candidate variants 56 57 underwent functional validation using diverse experimental approaches.

**Results** Isoform-level re-quantification of retinal gene expression revealed 76 IRD genes with a non-canonical retina-enriched isoform, of which 20 display a fully distinct 5'UTR compared to that of their canonical isoform. Depending on the probe-design 3-20% of IRD genes have 5'UTRs fully captured by WES. After analyzing these regions in both IRD cohorts we prioritized 11 (likely) pathogenic variants in 10 genes (*ARL3, MERTK, NDP, NMNAT1, NPHP4, PAX6, PRPF31, PRPF4, RDH12, RD3*), of which 8 were novel. Functional analyses further supported the pathogenicity of 2 variants. The *MERTK*:c.-125G>A variant, overlapping a transcriptional

65	start site, was shown to significantly reduce both luciferase mRNA levels and activity. The
66	RDH12:c123C>T variant was found <i>in cis</i> with the reported hypomorphic RDH12:c.701G>A
67	(p.Arg234His) variant in 11 patients. This 5'UTR variant, predicted to introduce an upstream
68	open reading frame, was shown to result in reduced RDH12 protein but unaltered mRNA
69	levels.
70	Conclusions   This study demonstrates the importance of 5'UTR variants implicated in IRDs
71	and provides a systematic approach for 5'UTR annotation and validation that is applicable to
72	other inherited diseases.
73	Keywords
74	5'untranslated region (5'UTR), upstream open reading frame (uORF), non-coding variation,
75	whole genome sequencing (WGS), whole exome sequencing (WES), in silico prioritization,
76	variant interpretation, functional studies, inherited retinal disease (IRD).
77	
78	
79	
80	
81	
82	
83	
84	

### 86 Background

Among the numerous non-coding regulatory regions found across the human genome, 5' 87 untranslated regions (5'UTRs) are major determinants of post-transcriptional control and 88 translation efficiency<sup>1,2</sup>. These regions, with an average length of about 200 nucleotides in 89 humans, are located immediately upstream from protein-coding sequences and include the 90 Kozak consensus sequence around the AUG start codon<sup>3</sup>. 5'UTRs harbor numerous cis-91 92 regulatory elements such as internal ribosomal entry sites (IRES) and upstream open reading 93 frames (uORFs), which can recruit scanning ribosomes and initiate translation<sup>4</sup>. In particular, uORFs, defined by an upstream start codon in-frame with a stop codon preceding the end of 94 the primary open reading frame, can decrease downstream protein expression up to 80%<sup>5</sup>. 95 96 Furthermore, 5'UTRs can serve as platforms for the formation of secondary and tertiary mRNA structures like stem-loops, hairpins, and RNA G-quadruplexes which further influence mRNA 97 98 translation<sup>6,7</sup>. Given the critical importance of 5'UTRs as modulators of protein expression, genetic variation within these regions can contribute to disease pathogenesis, as shown by 99 several examples in a wide range of inherited diseases<sup>8–11</sup>. 100

With the expanding implementation of massively parallel sequencing technologies in clinical practice, the rare disease field has witnessed a true paradigm shift enabling improved molecular diagnosis for many affected individuals<sup>12–15</sup>. Despite these advancements, and although this varies greatly across individuals with diverse clinical indications, a significant fraction of cases with suspected Mendelian disorders remains unsolved<sup>12,13,16–18</sup>.

To date, 5'UTR variants are often not evaluated because of the multiple challenges they entail.
 Firstly, detection relies on inclusion of these non-coding regions in targeted resequencing
 panels or whole genome sequencing, which has been limited to date<sup>19</sup>. Secondly,
 interpretation of the effect is more difficult due to different mechanisms<sup>8</sup> and our relative lack

of understanding of the functional consequences of 5'UTR variants. Finally, functional evidence is necessary to support their pathogenicity and hence confirm the molecular diagnosis. Recently, to close the annotation and interpretation gap, several *in silico* tools<sup>20–26</sup> and guidelines<sup>27</sup> have been developed, although their specific applicability to the accurate and comprehensive interpretation of the diverse pathogenic mechanism of 5'UTR variants is yet to be fully established.

A clear instance of both the effectiveness and remaining challenges of clinical large-scale 116 genome analyses can be found in inherited retinal diseases (IRDs)<sup>28-31</sup>. IRDs comprise a 117 genetically and phenotypically diverse constellation of visually debilitating conditions 118 affecting over 2 million people globally<sup>32,33</sup>. With over 290 known disease genes<sup>34</sup>, diverse 119 120 modes of inheritance<sup>29</sup>, intersecting phenotypes<sup>35,36</sup>, and available automated approaches to variant interpretation, establishing a genetic diagnosis in IRD patients can be challenging. Even 121 after the use of unbiased approaches such as whole exome (WES) and whole genome 122 sequencing (WGS), up to 50% of cases remain unsolved <sup>15,28,37–39</sup>, and hence without the 123

124 possibility of potential clinical intervention including gene therapy-based treatments<sup>40,41</sup>.

Recent studies have revealed an important contribution of non-coding variation to IRDs, particularly with the identification of deep-intronic mis-splicing variants<sup>39,42,51,43–50</sup>. Moreover, there is a growing body of evidence supporting the emerging role of genetic variation affecting *cis*-regulatory regions in the molecular pathogenesis of IRDs<sup>45,48,52–56</sup>. However, thus far only a few 5'UTR variants have been reported to be implicated in ocular diseases, including IRDs<sup>48,53,54,57–59</sup>, but no large-scale studies have been performed yet.

In this work, we conducted a systematic evaluation of 5'UTR variation in IRD genes using WGS
 and WES data derived from two IRD cohorts comprising 2,417 participants of the 100,000
 Genomes Project<sup>12</sup> and 1,682 local cases, respectively. Firstly, we obtained a comprehensive

134 selection of 5'UTRs of the most abundant canonical as well as non-canonical protein-coding IRD gene isoforms by performing transcript-level re-quantification of retinal expression data. 135 We then screened these regions for variants in both IRD cohorts and developed a prioritization 136 strategy to identify candidate pathogenic 5'UTR variants. This allowed us to identify 11 137 potentially causative 5'UTR variants, 10 of which were found in unsolved cases. Functional 138 139 validation of the predicted pathogenetic mechanism was performed for 4 of these, further supporting the potential implication in disease for 2 variants. Overall, we show that 5'UTRs 140 represent understudied targets of non-coding variation that can provide novel molecular 141 diagnoses in IRDs and demonstrate the importance of reassessing these regions in existing 142 exome and genome sequencing data. 143

### 144 Methods

### Re-analysis of retinal RNA-seq data and selection of retina-enriched isoforms of IRD genes 145 We retrieved paired-end FASTQ files (GSE115828) derived from human postmortem retina 146 samples characterized by Ratnapriya et al., (2019)<sup>60</sup>. Only samples derived from donor retinas 147 148 showing no features of age-related macular degeneration were evaluated (n=102). Transcripts were quantified through pseudoalignment by *Kallisto<sup>61</sup>* (v.0.46.1) using default parameters. 149 Abundance estimates in transcripts per million (TPM) for all annotated transcripts (Ensembl 150 human release 107) were retrieved. A custom R (v.4.0.2) script was used for annotating each 151 transcript with its corresponding gene and biotype and flagging them as canonical and/or 152 153 belonging to the Matched Annotation from NCBI and EMBL-EBI (MANE) and MANE Plus Clinical set (version 1.0)<sup>62</sup>. For each group of isoforms belonging to each gene, we computed 154 the average of abundance estimates across all samples and the isoform exhibiting the highest 155 average among its corresponding group was deemed retina-enriched. This dataset was further 156

filtered by retaining only protein-coding isoforms derived from selected genes, namely IRD
genes listed in either the *Retinal disorders panel* (v2.195) from Genomics England PanelApp<sup>63</sup>
or RetNet (<u>https://sph.uth.edu/retnet/</u>) (**Table S1**). Additionally, we integrated cap analysis
gene expression sequencing (CAGE-seq) data derived from fetal and adult retina (FANTOM5<sup>64</sup>
Robust Peak Set using an expression RLE normalized threshold >1) to evaluate the confidence
of the annotated transcription start sites (TSS) of the selected transcripts in retina.
To aid tiering of variants, the Genomics England PanelApp<sup>63</sup> gene color-coded rating system

was used: genes with diagnostic-grade rating, borderline evidence and research candidates
were flagged with green, amber, and red, respectively. To further assess the retinaenrichment of specific isoforms, their loci were inspected using an integration of multiple
publicly available multi-omics datasets derived from human retina (Table S2).

### 168 Comparison of 5'UTRs of canonical and non-canonical isoforms and selection of 5'UTR 169 variant search space

The exact genomic coordinates of the start and end positions of the 5'UTRs of all genes were 170 171 downloaded from Ensembl biomart (Human Ensembl Genes 107, GRCh38.p13) and filtered to 172 only include the transcripts defined above. We first assessed the number of exons composing these 5'UTRs to identify which IRD genes have spliced 5'UTRs. For each IRD gene for which a 173 174 retina-enriched non-canonical isoform was identified, we compared the canonical and noncanonical 5'UTRs and computed their respective overlap. The calculated overlaps were then 175 used to classify these genes into three different categories, namely genes with transcripts 176 177 displaying: (i) fully distinct 5'UTRs, (ii) partly overlapping 5'UTRs, and (iii) fully overlapping 178 5'UTRs.

For each 5'UTR exon of all selected transcripts, we defined a near-splice region by including
25-bp intronic sequence up- and downstream of its respective splice donor and acceptor sites

(excluding promoter and coding sequences). The resulting coordinates were annotated with
their corresponding transcript identifier and gene name and stored into a sorted BED file
(herein after referred to as 5'UTR analysis file) for downstream variant assessment.

### 184 Evaluation of 5'UTR capture by whole-exome sequencing

We assessed the performance of exome captures of the selected 5'UTRs based on the designs 185 provided by the kits which were mostly used for the generation of our in-house WES data, 186 namely the SureSelect Human All Exon V6 and SureSelect Human All Exon V7 (Agilent 187 Technologies), as well as a selection of the most recent versions of commonly used kits from 188 189 4 different providers: SureSelectXT Human All Exon V8 (Agilent Technologies), KAPA 190 HyperExome V2 (Roche), Twist Exome 2.0 (Twist), Illumina Exome Panel v1.2 (Illumina). BED files containing the genomic coordinates of the capture regions were downloaded from the 191 corresponding design catalogs and intersected with the coordinates of the 5'UTRs of interest 192 using *bedtools intersect* (v2.26.0)<sup>65</sup> with default parameters. For uniformity, only the capture 193 regions were used to compare between the different designs. Additionally, for the SureSelect 194 195 Human All Exon V6 and SureSelect Human All Exon V7 kits (Agilent Technologies) both the 196 strict union of all regions covered by baits and a version padded by ±50bp extending into intronic regions were considered for the intersections. A custom Python (v.3.6.8) script was 197 198 then used to compute for each IRD gene the length proportion (%) of its 5'UTR captured by these kits. 199

### 200 Search of 5'UTR variants in IRD genes submitted to ClinVar

The ClinVar database (ClinVar) was downloaded in a tab-delimited format<sup>66</sup> directly from the FTP site (<u>https://ftp.ncbi.nlm.nih.gov/pub/clinvar/</u>; version from 2023-03-18) and pre-filtered to keep only entries from the GRCh38.p13 build. The resulting file was further filtered to retrieve variants located within the regions defined in the *5'UTR analysis file*. Large copy number gain/loss variants extending into coding regions as well as variants with a proteinaltering or synonymous annotation for the canonical transcript were removed from this analysis.

### 208 Cohort selection

To assess the contribution of 5'UTR genomic variation to IRDs, individuals from two different cohorts were selected for this study: (i) 2,397 participants (2,100 probands) from a sub-cohort of the Rare Disease arm of the 100,000 Genomes Project (Genomics England –GE– cohort) affected by posterior segment abnormalities (**Table S3**); (ii) an IRD sub-cohort of 1,682 cases (1,030 probands) with a WES analysis performed at the Center for Medical Genetics Ghent (CMGG cohort). In both cases, sequencing data aligned to GRCh38 build were included. The 100,000 Genomes Project Protocol has ethical approval from the HRA Committee East of

England – Cambridge South (REC Ref 14/EE/1112). This study was registered with Genomics England within the *Hearing and sight* domain under Research Registry Projects 465. This study was approved by the ethics committee for Ghent University Hospital (B6702021000312) and performed in accordance with the tenets of the Helsinki Declaration and subsequent reviews.

220 Sequencing and variant analysis

We interrogated WGS and WES data from the two cohorts described above to detect germline single-nucleotide variants (SNVs) and small insertions and deletions (indels) overlapping the regions defined in the *5'UTR analysis file*. The sequencing and bioinformatic pipelines used for processing genome data derived from the participants of the GE cohort have been described previously<sup>12</sup>. 226 Samples from the CMGG cohort were tested using WES with the SureSelect Human All Exon V6, SureSelect Human All Exon V7 (Agilent Technologies) or HyperExome (Roche) enrichment 227 kits and sequenced on HiSeg 3000 or NovaSeg 6000 instruments (paired-end 150 cycles) 228 (Illumina). Reads were aligned to the human reference genome (GRCh38 build) with BWA 229 (v0.7.15)<sup>67</sup> and GATK HaplotypeCaller (v3.82)<sup>68</sup> was used for calling SNVs and indels. Resulting 230 variant call format (VCF) files from both cohorts were subsequently parsed based on the 231 regions of interest using BCFtools (v1.9)69. Only variants satisfying the filter criteria for 232 sequencing depth (DP>10) and genotype quality (GQ>15) were retrieved. 233

### 234 Variant annotation and prioritization

235 From each cohort, a file containing unique variants was created and formatted so that it could be annotated with the *Ensembl Variant Effect Predictor*<sup>70</sup> (VEP, release 107). Apart from gene 236 and transcript information, each variant was annotated with frequency data retrieved from 237 gnomAD<sup>71</sup> allele frequencies, splicing (dbscSNV<sup>72</sup>, SpliceAl<sup>23</sup>, (genomes, v3.1.2) 238 MaxEntScan<sup>73</sup>), pathogenicity predictions (EVE<sup>74</sup>, CADD<sup>75</sup>), and regulatory data<sup>76</sup>. The recently 239 developed UTRannotator<sup>20</sup> tool was used to annotate variants that create or disrupt uORFs. 240 The classical<sup>77</sup> and retinal<sup>78</sup> Kozak consensus sequences were considered altered when 241 variants were identified within the position range -1 to -10 relative to the main AUG (canonical 242 start codon). In addition, nucleotide frequency plots corresponding to the Kozak sequences of 243 the retina-enriched and not retina-enriched transcripts evaluated in this study were generated 244 using were generated with WebLogo<sup>79</sup> (v.3.7.12). Annotation data tables containing predicted 245 changes in translational efficiency<sup>80</sup> and secondary structure minimum free energy affecting 246 double-stranded RNA or G4 quadruplex structures<sup>81</sup> were downloaded (*5utr ['suter'*]: 247 https://github.com/leklab/5utr) and queried for the variant positions using tabix<sup>82</sup> (v.1.7-2); 248 further evaluation of changes in mRNA secondary structure was performed using the Ufold<sup>83</sup> 249

(v.1.2), *REDfold*<sup>84</sup> (v1.14.alpha), and *MXfold2*<sup>85</sup> (v0.1.2) tools. To assess whether variants were
 located within TSS relevant to retinal gene expression, we made use of the CAGE-seq data
 described above. Translation initiation-related feature data from the Human Internal
 Ribosome Entry Sites (IRES) Atlas<sup>86</sup> was also queried to annotate variants found within these
 regions involved in cap-independent translation initiation.

255 Annotated 5'UTR variants were classified into the following 7 categories: (i) uAUG gained, (ii) change in existing uORF, (iii) alteration of classical or retinal primary Kozak context, (iv) 256 257 splicing, (v) change in translational efficiency (TE), (vi) change in secondary structure minimum free energy, and (vii) overlapping a retinal transcription start site and/or an IRES. Variants 258 were first selected when their minor allele frequency was lower than 2% in all populations. 259 260 The resulting variants were further filtered using specific criteria for each category: (i) uAUG created in a strong or moderate Kozak context, (ii) natural uAUG loss, (iii) variant located in 261 positions -3, -4, -5, -6, or -9, (iv) any SpliceAl Delta Score (DS\_AG, DS\_AL, DS\_DG, DS\_DL) higher 262 than 0.2, (v) |log2FC|≥0.5, (vi) |FC| ≥1.5, (vii) variant located within a TSS or IRES. Variants for 263 264 which the inheritance pattern and phenotype of the patient were compatible with the gene in which the 5'UTR variant was identified were selected as candidates. This prioritization 265 266 procedure is depicted in Figure 1. For comparing the proportion of variants for each category between cohorts, the statistical analysis was performed in R using the  $\chi^2$ -test. Finally, for each 267 candidate variant identified in unsolved cases, an additional screening was performed to 268 discard (likely) pathogenic variants, both SNVs and structural variants (SVs), in other IRD genes 269 270 that could provide an alternative molecular diagnosis. For the cases from the GE cohort in 271 which the identified 5'UTR variant remained as candidate, we requested to have a clinical 272 collaboration with Genomics England.

#### 273 Cell culture

ARPE-19 (ATCC, CRL-2302<sup>™</sup>) and HEK-293T cells (ATCC CRL-3216<sup>™</sup>) cells were grown in either
Dulbecco's minimal essential medium (DMEM) with phenol red (Thermo Scientific Life
Technologies) or DMEM:F12 (Gibco) medium supplemented with 10% fetal bovine serum
(Gibco), 1% penicillin-streptomycin (Gibco), 1% non-essential amino acid solution (Gibco), and
0.1% amphotericin B (Gibco), respectively. Cells were cultured at 37°C and 5% CO2 and tested
for mycoplasma contamination prior to use.

To perform functional studies of the identified 5'UTR *ARL3* variant, lymphocytes from affected carriers (n=2) were isolated from EDTA blood using Lymphoprep (STEMCELL technologies). For each sample two cultures were started in RPMI medium with 10% fetal bovine serum and substituted with interleukin-2 and phytohaemagglutinin. One of both cultures was treated for four hours with puromycin (200  $\mu$ g/mL) prior to RNA extraction to suppress nonsensemediated decay.

### 286 Cloning and mutagenesis

In order to evaluate the functional effect of 3 selected 5'UTRs variants (RDH12:c.-123C>T, 287 MERTK:c.-125G>A, PAX6:c.-44C>T), we cloned the wild-type 5'UTR of interest (IDT gBlock) into 288 289 a psiCHECK<sup>™</sup>-2 dual luciferase vector (Promega) using the Cold Fusion cloning kit (Sanbio BV). 290 The recombinant vectors were then amplified in One Shot TOP10 Chemically Competent E. 291 coli cells (Invitrogen) and purified using the NucleoBond Xtra Midi kit (Filter Service S.A). For the generation of the overexpression construct to further assess the RDH12:c.-123C>T variant, 292 we designed a gBlocks<sup>™</sup> fragment comprising the wild-type 5'UTR and coding sequence (CDS) 293 294 of RDH12; both sequences were modified to include downstream Myc and FLAG in-frame tags 295 to evaluate the translation of the uORF introduced by the *RDH12*:c.-123C>T variant and RDH12 protein levels, respectively. These fragments were then cloned into a pcDNA<sup>™</sup>3.1<sup>(+)</sup> 296 (Invitrogen) vector by restriction-ligation cloning and the recombinant vectors were amplified 297

and purified as described above. For all constructs, 5'UTRs variants were introduced using the
Q5 Site-Directed Mutagenesis Kit (NEB) using variant-specific primers designed with the *NEBaseChanger* tool. The sequence of each insert was confirmed by Sanger sequencing using
the BigDye Terminator v3.1 kit (Life Technologies) and/or long-read whole plasmid sequencing
(Plasmidsaurus). A schematic overview of these constructs is shown in Figure S1. All primer
sequences can be found in Table S4.

### 304 **Dual luciferase assays**

ARPE-19 cells were seeded in a 24-well plate (Greiner Bio-One BVBA) at a density of 50,000 305 306 cells/well in 1mL of medium without antibiotics to reach 70-90% confluence at transfection 307 (18-24h after plating). Cells were transfected at a 3:1 reagent to plasmid DNA ratio using the TransIT-X2<sup>®</sup> Dynamic Delivery System (Mirus Bio) according to the manufacturer's 308 instructions. After 24 h, cells were lysed, and luciferase activity was detected using the Dual-309 Glo<sup>®</sup> Luciferase Assay System (Promega) in a Glomax 96-Microplate Luminometer (Promega). 310 Each transfection was performed in triplicate and each experiment was repeated at least three 311 312 times to ensure reproducibility. For each well, the ratio of *Renilla* luciferase activity was 313 normalized to Firefly luciferase activity. A custom R script was used to evaluate the effect of each variant on luciferase activity through a linear mixed effects model (implemented in the 314 *Ime4* package<sup>87</sup>) having set the luciferase vector as fixed effect and the biological replicate as 315 random effect. 316

### 317 RNA isolation and quantitative polymerase chain reaction (qPCR)

Total RNA was extracted using either the RNeasy Mini kit<sup>®</sup> (Qiagen) (ARPE-19 and HEK-293T cells) or the Maxwell RSC simply RNA kit (Promega) (cultured lymphocytes) according to the manufacturer's instructions. Isolated RNA underwent DNase treatment (ArcticZymes, Tromsø, Norway) prior to cDNA synthesis with the iScript cDNA Synthesis Kit (Bio-Rad Laboratories). For each cDNA sample, qPCR assays were prepared using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories) and run on LightCycler 480 System (Roche). Data were analyzed with *qbase+*<sup>88</sup> (CellCarta, v.3.4) and normalized either to a set of housekeeping genes (*YWHAZ*, *HPRT1*, *HMBS*, *SDHA*) or *Firefly* luciferase for normalization of *Renilla* luciferase mRNA levels. All primer sequences can be found in **Table S4**. Statistical analyses were performed in R using the Wilcoxon rank sum test.

### 328 **Overexpression and immunoblotting**

329 To perform immunoblotting of RDH12 and the predicted peptide encoded by the uORF 330 introduced by the RDH12:c.-123C>T variant, ARPE-19 cells were seeded in 12-well plates (Greiner Bio-One BVBA) at a density of 100,000 cells/well, allowed to settle overnight, and 331 then transfected with the wild-type and mutant *RDH12* overexpression vectors using the 332 TransIT-X2<sup>®</sup> Dynamic Delivery System (Mirus Bio) according to the manufacturer's 333 instructions. The pcDNA<sup>™</sup>3.1<sup>(+)</sup> (Invitrogen) backbone vector was transfected as negative 334 335 control. Four hours prior to RNA and protein isolation, cells were treated with 10µM MG-132 336 proteasome inhibitor (Merck Life Science). For total protein extraction, cells were lysed with RIPA Buffer (Sigma-Aldrich) including protease inhibitory cocktail (Roche Diagnostics), 337 phosphatase inhibitory cocktail 2, and phosphatase inhibitory cocktail 3 (Sigma-Aldrich). 338 Protein concentrations were measured using the Pierce<sup>™</sup> BCA Protein Assay kit (Fisher 339 Scientific). After centrifugation and reduction with 1M DTT (Sigma-Aldrich), protein lysates 340 341 were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis using either 342 NuPAGE<sup>™</sup> 4–12% Bis-Tris (RDH12 blot) or Novex<sup>™</sup> 16% Tricine (uORF blot) Protein Gels (Fisher Scientific) with a ladder (Precision Plus Protein All Blue Standards, Bio-Rad Laboratories). 343 Proteins were then transferred to a nitrocellulose membrane using the iBlot 2 Dry Blotting 344

345 System (Thermo Fisher Scientific). Membranes were blocked for 2 hours at room temperature in 2% ECL<sup>™</sup> Blocking Agent (Cytiva Amersham) and incubated at 4°C overnight with anti-FLAG 346 (1:1000, F1804, Merck Life Science) or anti-Myc (1:1000, ab9106, Abcam) primary antibodies. 347 Membranes were subsequently incubated for 2 hours at room temperature with the 348 appropriate horseradish-peroxidase-conjugated secondary antibody (1:2500, 7076S or 7074S, 349 350 Cell Signaling Technologies) and revealed with the SuperSignal<sup>™</sup> West Dura Extended Duration Substrate (Fisher Scientific). Membranes were scanned with an Amersham Imager 680 system 351 352 (GE Healthcare Life Sciences). Protein quantification was performed by firstly stripping the membranes with Restore<sup>™</sup> PLUS Western Blot Stripping Buffer (Thermo Scientific), incubating 353 them for 1 hour at room temperature with a primary antibody against  $\beta$ -tubulin (1:2500, 354 355 ab6046, Abcam) and for 2 hours with a horseradish-peroxidase-conjugated secondary antibody (1:2500, 7074S, Cell Signaling Technologies). RDH12 (FLAG) signal intensity 356 quantification was achieved using *ImageJ* (NIH, v.1.50i) and normalized to the amount of  $\beta$ -357 tubulin. 358

To further assess the translation of the peptide encoded by the uORF introduced by the *RDH12*:c.-123C>T variant, transfected HEK-293T cells were lysed as previously described, and protein lysates incubated at 4°C overnight with Dynabeads Protein A (Thermo Fisher Scientific), to which the anti-Myc primary antibody (1:1000, ab9106, Abcam) was bound. Bound proteins were subsequently eluted and subjected to anti-Myc Western Blot analysis as described above. Statistical analyses were performed in R using the Student's t-test.

#### 365 Screening of RDH12: c.-123C>T variant

The *RDH12*:c.-123C>T 5'UTR variant was shared with members of the European Retinal Disease Consortium (ERDC: https://www.erdc.info/) to evaluate its pathogenicity and identify

additional carriers of the *RDH12*:c.701G>A (p.Arg234His) missense variant to confirm its *cis*-

369 configuration. Primer sequences for PCR and Sanger sequencing are listed in **Table S4**.

370 **Results** 

# Isoform-level re-quantification of retinal gene expression reveals differential 5'UTRs of IRD genes

To obtain a relevant selection of 5'UTRs for downstream variant screening, we performed a 373 374 transcript-level re-analysis of RNA-seq data to identify protein-coding non-canonical isoforms 375 with relevant retinal expression i.e., higher than its respective canonical isoform, to be 376 retained in addition to the canonical isoforms. A total of 454 canonical and non-canonical transcripts belonging to 378 IRD genes were thus selected (with maximum of 2 isoforms per 377 gene) (Table S5), from which their 5'UTRs were retrieved, resulting in 638 genomic regions 378 379 (Table S6). Considering these 454 transcripts, the 5'UTRs of approximately 62% of IRD genes (233/378) are only part of the first coding exon while 33% of IRD genes (126/378) have 380 exclusively transcripts with spliced 5'UTRs, i.e., their 5'UTR comprise additional full non-coding 381 382 exons. A minor fraction (19/378) of genes has isoforms with both spliced and non-spliced 5'UTRs (Figure 2A; Table S7). Of the 76 IRD genes for which a retina-enriched non-canonical 383 384 isoform was identified, 20 display a fully distinct 5'UTR compared to the one of their corresponding canonical isoforms (Figure 2B; Table S8). For six of these, the non-canonical 385 TSS is further supported by CAGE-seq data derived from both adult and fetal retina (**Table S5**; 386 Figure S2). Two remarkable examples are CRB1 and RIMS2, for which the non-canonical 387 388 isoforms (ENST00000681519.1: 48.38±14.97 TPM; ENST00000436393.6: 41.58±12.35 TPM) 389 were found to be more abundant in retina compared to their respective canonical isoforms 390 (ENST00000367400.8: 2.54±3.88 TPM; ENST00000696799.1: 12.19±3.85 TPM). These findings

391 were also supported by the integration of multiple multi-omics datasets derived from human

392 retina (Figure S3; Table S2).

### 393 A substantial fraction of 5'UTRs can be captured by whole-exome sequencing

394 In view of the large volume of existing WES data, we evaluated the performance of six recent and commonly used commercial exome capture designs from four different providers on the 395 selected 5'UTRs of IRD genes. The kits considered in this analysis were found to display a 396 397 variable performance with an average coverage of the selected 5'UTRs ranging from 7% (Twist 398 Exome 2.0) to 39% (Illumina Exome Panel v1.2) (Figure 3A; Table S9). Besides, the fraction of 399 IRD genes with 5'UTRs fully captured ranged from 3% (10/378) to 20% (73/378). Regarding 400 the kits that were mostly used in-house (SureSelect Human All Exon V6 and SureSelect Human All Exon V7), although a slightly higher 5'UTR capture was observed for the kit with a higher 401 402 amount of probes (SureSelect Human All Exon V6) (Figure S4; Table S10), we found that approximately 15% of IRD genes (57/378) have the selected 5'UTRs fully captured. This 403 fraction increased up to 39% (148/378) (Figure 3B; Table S10) if a padded bait design, 404 405 including all regions that can be confidently genotyped, was considered.

## A retrospective analysis of 5'UTR variants reported in IRD genes reveals a majority classified as Variants of Uncertain Significance (VUS)

A total of 1,547 5'UTR variants in IRD genes have been submitted to the ClinVar database thus far (**Table S11**). All variants except 4 have been clinically interpreted. Only 2% (31/1,547) of the variants have been classified as pathogenic or likely pathogenic, of which 32% (10/31) and 16% (5/31) were found in the *PAX6* and *NMNAT1* genes, respectively. On the other hand, 34% (527/1,547) of the 5'UTR variants have been classified as benign or likely benign, of which no single gene was found to account for more than 5% of these variants. While 5% (81/1,547) of

- 414 the variants had conflicting interpretations of pathogenicity, the largest fraction comprising
- 415 58% (904/1,547) of all variants have been classified as VUS.

### 416 Analysis of 5'UTRs in WGS and WES data of two IRD cohorts reveals rare and ultra-rare

417 variants predicted to affect 5'UTR function

To systematically assess the contribution of 5'UTR genomic variation to IRDs, we performed a 418 variant analysis within the selected 643 genomic regions in affected individuals from two 419 420 different IRD sub-cohorts, namely the GE (n=2,397 WGS) and CMGG (n=1,682 WES) cohorts. We identified a total of 2,898 and 381 distinct 5'UTR variants within the GE and CMGG cohorts, 421 422 respectively. The majority of these variants (2,637/2,898 and 334/381) had a minor allele 423 frequency (MAF) lower than 2% in all populations and a substantial fraction (506/2,898 and 92/381) was found to be absent from all reference population public databases. To aid the 424 interpretation of these 5'UTR variants, we classified them into 7 (non-mutually exclusive) 425 categories according to their in silico predicted functional consequences (Figure 1). A 426 summarized overview of the number of variants that remained after classification and 427 428 category-specific filtering can be found in **Table 1**. Out of the 1,450 remaining variants 429 (Dataset S1), 370 were present in more than one category. Of the remaining variants assigned to a single category, the bulk corresponded to variants overlapping a retinal TSS or an IRES 430 431 (761/1,450; 221 -TSS-, 488 -IRES-, 52 -TSS & IRES-), followed by variants with a predicted change in secondary structure minimum free energy (204/1,450). When comparing the 432 number of variants in each category between the two cohorts, we observed statistically 433 434 significant differences in the number of variants overlapping a retinal TSS and/or IRES, for 435 which the proportion of variants was higher for the WGS-based GE cohort compared to the WES-based CMGG cohort (~55% and ~35% respectively, p<0.05). These differences are most 436 likely due to the expanded capture of regions including TSS allowed by the use of WGS in the 437

- 438 GE cohort. Additionally, it is noteworthy that for the IRD genes with 5'UTRs harboring IRES
- 439 (92/378), these elements were found to span on average 61% of the 5'UTR and even its entire
- 440 length for certain genes (12/92) (**Table S12**).
- 441 Table 1. Summarized overview of the number of 5'UTR variants that remained after functional
- 442 classification and filtering.

	GE cohort	CMGG cohort	Total	%
uAUG gained	30	5	35	2.41
Change in existing uORF	17	1	18	1.24
Alteration of classical or retinal primary Kozak context	16	6	22	1.52
Splicing	29	10	39	2.69
Change in translational efficiency	1	0	1	0.07
Change in secondary structure minimum free energy	194	10	204	14.07
Overlapping a retinal transcription start site or an IRES	692	69	761	52.48
> 1 category	276	94	370	25.52
Total	1255	195	1450	

Abbreviations: CMGG, Center for Medical Genetics Ghent; GE, Genomics England; IRES, internal ribosomal entry
 site; uORF, upstream open reading frame.

## Systematic variant evaluation allows the prioritization of candidate pathogenic 5'UTR variants

To enhance the likelihood of identifying potential pathogenic 5'UTR variants, we prioritized the ones with higher predicted impact based on specific criteria for each category (**Figure 1**) and for which the inheritance patterns and reported phenotypes fitted the genes in which the 5'UTR variants had been identified. The application of this prioritization procedure is illustrated in **Table S13**. We prioritized 11 candidate pathogenic 5'UTR variants. Of these, 10 were found in unsolved cases and 8 have not been reported before. Of note, although initially identified through WGS, 6 of these variants would also be covered by WES. An overview of 454 the genetic, phenotypic, and *in silico* prediction details of these variants is shown in **Table 2**.

455 The pedigrees of these families including variant segregation are shown in **Figure S5**.

Four of these variants were found to alter splicing in genes linked to autosomal dominant 456 (PRPF31), autosomal recessive (NMNAT1) and X-linked (NDP) disease. The NDP:c.-70G>A and 457 PRPF31:c.-9+1G>A variants have recently been reported by Daich Varela et al. (2022)<sup>48</sup>. We 458 459 identified a de novo variant (PRPF31:c.-9+1G>T) in the same 5'UTR position of PRPF31 in a sporadic case with rod-cone dystrophy in which bi-allelic GRM6 variants had been identified, 460 461 one of them reported as likely benign (Table S14). Variants in GRM6 cause autosomal recessive congenital stationary night blindness<sup>89</sup>, which is different from the clinical diagnosis 462 in this proband. The NMNAT1:c.-57G>A variant was found in an individual with macular 463 dystrophy that carries in trans an extremely rare missense variant for which in silico 464 465 predictions support a pathogenic effect.

Changes in secondary structure were predicted for 4 variants in genes linked to autosomal
dominant (*ARL3, PAX6*) and autosomal recessive (*MERTK, RD3*) disease (Figure S6). Given the
inheritance pattern and *in silico* predictions, a gain-of-function effect was hypothesized for
the *ARL3*:c.-88G>A and *PAX6*:c.-44T>C variants. Both the *MERTK*:c.-125G>A and *RD3*:c.394G>A variants were identified in homozygous state and found to overlap their respective
TSS.

The introduction of an uORF was predicted for 2 variants in the *NPHP4* and *RDH12* genes. In contrast to the uORF created by the *RDH12*:c.-123C>T variant, the one introduced by the *NPHP4*:c.-21C>T variant is out-of-frame and overlaps the CDS. Although no segregation could be established for this case with non-syndromic rod-cone dystrophy, an ultra-rare missense *NPHP4* variant with pathogenic *in silico* predictions was identified.

Only one variant in a gene linked to dominant disease (*PRPF4*) was predicted to affect the primary Kozak consensus sequence. The *PRPF4*:c.-6C>T variant results in a transition to an infrequent nucleotide at this position within the Kozak consensus sequences derived from the IRD gene isoforms selected in this study (**Figure S7**). This variant was found in a sporadic case with rod-cone dystrophy in which 2 likely pathogenic variants have been identified in the *ITF140* gene (**Table S14**); segregation analysis was not possible to establish the phase of any of these alleles.

484 Four of the variants (*ARL3*:c.-88G>A, *MERTK*:c.-125G>A, *PAX6*:c.-44T>C, *RDH12*:c.-123C>T)

485 were selected for functional validation using diverse multiple experimental approaches.

### 486 Downstream functional analyses support the pathogenicity of the *MERTK*:c.-125G>A and 487 *RDH12*:c.-123C>T variants

488 Depending on the tissue-specific gene expression and availability of patient material, we conducted either in vitro evaluation in ARPE-19 cells (dual luciferase assays or 489 overexpression), or mRNA expression analysis in patient-derived lymphocyte cultures (Figure 490 491 **4A**). The *RDH12*:c.-123C>T and *MERTK*:c.-125G>A variants were found to result in a significant 492 decrease in luciferase activity (Figure 4B). To further elucidate the underlying mechanism, Renilla mRNA expression analysis was performed. Relative Renilla luciferase mRNA levels 493 494 remain unchanged for RDH12:c.-123C>T, whereas a significant decrease was observed for MERTK:c.-125G>A (Figure 4C), hence suggesting a translational and a transcriptional effect for 495 these variants, respectively. 496

Taking advantage of the expression of *ARL3* in accessible tissues, we performed qPCR-based quantification of *ARL3* mRNA abundance in lymphocyte cDNA from the two affected siblings in whom we identified the *ARL3*:c.-88G>A variant and five healthy controls. No significant differences were observed in *ARL3* mRNA abundance between the affected carriers and 501 controls (**Figure 4D**). Interestingly, *ARL3* expression levels were slightly higher in the patient 502 samples derived from the lymphocyte cultures treated with puromycin, a translation inhibitor 503 used to suppress nonsense-mediated mRNA decay, compared to the corresponding untreated 504 samples and controls. Therefore, although the *ARL3*:c.-88G>A variant was not predicted to 505 affect splicing, we also performed Sanger sequencing on the cDNA derived from the 506 puromycin-treated and untreated patient lymphocyte cultures. Neither splicing defects nor 507 allele-specific expression were observed (*data not shown*).

In view of the negative results obtained for the *PAX6*:c.-44T>C and *ARL3*:c.-88G>A variants, the phenotypes of patients F9 and F10 were re-evaluated. Neither anterior segment abnormalities nor other clinical presentations compatible with a *PAX6*-related disease were observed in patient F9 or her affected relatives. Regarding F10, re-evaluation of one of the affected siblings revealed an acquired vascular ocular condition instead of an IRD.

### 513 The *RDH12*:c.-123C>T 5'UTR variant is found always *in cis* with the p.Arg234His hypomorphic

### allele and results in reduced RDH12 protein levels

We identified the *RDH12*:c.-123C>T variant in one solved case from the GE cohort characterized by bi-allelic *RDH12* coding variants (c.[701G>A];[c.735\_743del], p.[Arg234His]; [Cys245\_Leu247del]). The 5'UTR variant, reported as VUS in ClinVar, was found in *cis* with the p.Arg234His allele. Further evaluation of this 5'UTR variant in 10 additional *RDH12* bi-allelic patients from 8 families carrying the p.Arg234His variant revealed that the c.-123C>T and p.Arg234His variants always form a complex allele (**Table S15**). This was also shown for 7 carriers of the p.Arg234His variant affected by other pathologies (*data not shown*).

522 Here, we report the first patient who is homozygous for the *RDH12*: c.[-123C>T];[701G>A] 523 complex allele (**Table S15**). Compared to other patients carrying the 5'UTR variant *in trans* 

with a null *RDH12* allele<sup>90</sup>, patient F21 presents with a milder phenotype (mild decreased acuity (20/25 OD and OS) in fourth decade of life, foveal sparing maculopathy with a circumscribed area of atrophy within the vascular arcades, without a nasal component.

The c.-123C>T variant is predicted to introduce an uAUG into a strong Kozak consensus 527 sequence that is in-frame with a stop codon located 75 nucleotides downstream in the 5'UTR. 528 529 In view of the results obtained in the luciferase assays and the predicted uORF-introducing effect of the 5'UTR variant, we further inspected the potentially exclusive effect at the 530 translational level by assessing RDH12 mRNA abundance and protein levels in an 531 overexpression setting. Although we could not confirm translation of the 25-amino-acid-long 532 peptide predicted to be encoded by the uORF by co-immunoprecipitation (*data not shown*), 533 we observed unaltered mRNA but significantly (p<0.05) reduced RDH12 protein levels, 534 535 thereby providing further evidence for a post-transcriptional or translational effect (Figure 4E-F) which was already suggested by the mRNA evaluation in the luciferase assays. 536

### 537 **Discussion**

Given the emerging role of non-coding variation underlying IRDs<sup>45,48,52–55</sup> and the essential regulatory function of 5'UTRs<sup>2,6</sup>, we set out to evaluate their contribution to this heterogeneous group of disorders by analyzing, systematically annotating, filtering and prioritizing 5'UTR variants in two large IRD cohorts in combination with different experimental approaches for functional validation.

Thus far, only a few studies have implicated 5'UTR variation in the molecular pathogenesis of IRD cases<sup>48,53,54</sup>. Our retrospective analysis of 5'UTR variants in IRD genes listed in the ClinVar database<sup>66</sup> revealed that as many as 58% of all variants have been classified as VUS. A large fraction of the underrepresentation of (likely) pathogenic 5'UTR variants in clinical databases

547 can be explained by their exclusion from downstream tiering pipelines, which prioritize variants with protein-altering consequences and hence neglect the potential impact of 5'UTR 548 variants<sup>91</sup>. Furthermore, the identification of these variants is not always feasible by means of 549 commercial exome enrichment platforms, in particular when variants are found within 5'UTR 550 exons that are not part of or proximal to the first protein-coding exon<sup>19</sup>. Here, we show that 551 552 the enriched 5'UTR fraction is highly dependent on the WES capture kit used, and ranges from 7% to 39%. Overall, as previous studies have also argued<sup>92–94</sup>, our analysis underscores the 553 554 diagnostic value of re-analyzing exome data, in which causative variants might already be present but previously disregarded. 555

556 Furthermore, the identification of the genetic defects underlying IRDs is greatly impacted by the inherent complexity of the retinal transcriptional landscape. Variants in retina-enriched 557 558 isoforms and tissue-specific mis-splicing have been shown to be important molecular mechanisms underpinning disease pathogenesis and phenotypic heterogeneity<sup>95–99</sup>. As gene 559 isoforms can display differential 5'UTRs that can result in differential translational 560 efficiencies<sup>100</sup>, we performed a transcript-level re-analysis of retinal expression data to obtain 561 a relevant selection of 5'UTRs of IRD genes for downstream variant analysis. We identified 76 562 563 IRD genes with alternative isoforms exhibiting retinal expression levels higher than their respective canonical isoforms, of which 20 displayed a fully distinct 5'UTR. This analysis also 564 found the recently identified photoreceptor-specific non-canonical CRB1 isoform, which bears 565 a unique 5'UTR exon<sup>101</sup>. Similarly, we confirmed the retinal enrichment of an alternative 566 RIMS2 isoform containing an unconventional 5'UTR exon, which has been shown to be 567 photoreceptor-specific and functionally conserved in mouse (Del Pozo-Valero et al., 568 569 unpublished data). By revealing that a significant fraction of IRD genes express alternative

570 retinal isoforms, our analysis highlights the importance of isoform-aware variant annotation571 for adequate interpretation.

To aid the assessment of 5'UTR variant pathogenicity, in silico tools have recently been 572 developed, with an emphasis put on uORF-perturbing variants<sup>20,26</sup>. A systematic 573 characterization of this class of 5'UTR variants showed that they are subject to strong negative 574 575 selection, which could even be equivalent to that observed against missense variants<sup>11</sup>. However, thus far, these tools do not provide comprehensive annotations of all possible 576 effects 5'UTR variants can exert<sup>8</sup>. Here, we designed an integrative annotation of 5'UTR-577 informative features and built a prioritization strategy combining family and phenotypic data 578 to increase the probability of identifying potential pathogenic 5'UTR variants. Although we 579 580 performed these analyses in IRD cohorts, the features evaluated, and the methods presented in this study can be extrapolated and applied in any setting involving clinical interpretation of 581 582 5'UTR variation.

We prioritized 11 candidate pathogenic 5'UTR variants. The great majority of these variants 583 (8/11) have not been reported before, most likely due to their exclusion from routine 584 prioritization pipelines and subsequent clinical interpretation<sup>91</sup>. These 11 variants were 585 586 assigned to 5 of the 7 categories we defined to classify their potential functional consequences, thus reflecting the diversity in predicted functional effect. Of note, the majority 587 588 (4/11) was predicted to have an effect on splicing which, in line with our analysis revealing that almost one third of all IRD genes have their 5'UTRs spliced, supports that these regions 589 are also susceptible to disease-causing splicing defects. Notably, we also provided a set of 590 591 filtered annotated 5'UTR variants with in silico predictions pointing to a pathogenic effect that were not prioritized as candidates due to inconsistent genotypes or phenotypes in the patients 592 593 evaluated. Therefore, we cannot dismiss the possibility that these variants can have a

pathogenic effect when present in the right context, e.g. *in trans* with a second pathogenicallele in a gene linked to recessive disease.

596 Given the particular importance of providing functional evidence to support the pathogenicity of variants located within non-coding regions, we evaluated the predicted functional 597 consequence of 4 candidate variants. Despite the extreme rarity and disease co-segregation 598 599 of the PAX6:c.-44C>T variant, both the lack of functional evidence and the unusual phenotype established upon clinical re-evaluation indicate that this variant is not explaining the 600 phenotype. Likewise, we could not confirm the predicted effect of the ARL3:c.-88G>A variant 601 using accessible patient-derived material. The sibling of the proband was eventually 602 considered not affected by an IRD, indicating that the variant is either not causative, 603 604 incompletely penetrant, or simply a recessive allele. Interestingly, a phenotype similar to that of the proband has been associated with a pathogenic variant in this gene<sup>102</sup>, which could 605 suggest that this variant exerts a retina-specific effect that cannot be evaluated with the 606 current experimental setting. Nevertheless, it is important to note that in this case both 607 608 siblings have been studied by WES, but were not tested for known deep-intronic and structural variants. Before proceeding with further functional characterization of the ARL3:c.-88G>A 609 610 variant, WGS should thus be performed to confirm or rule out such variants. Altogether, these 611 results highlight the need and potential limitations of experimental assays to validate the 612 functionality of non-coding variants.

We could provide a novel molecular diagnosis in a patient with severe early-onset retinal dystrophy that remained unsolved after WGS screening. This individual was found to be a homozygous carrier for the extremely rare c.-125G>A variant in *MERTK*, overlapping its transcription start site, for which our *in silico* predictions pointed to an effect at the transcriptional level. A drastic reduction of luciferase activity accompanied by decreased

relative *Renilla* luciferase mRNA levels confirmed the hypothesized transcriptional effect of the variant, which is consistent with a loss of function of *MERTK*. To our knowledge, this is the first reported disease-causing 5'UTR variant in *MERTK*.

One of the candidate pathogenic 5'UTR variants was found in a case solved with bi-allelic 621 RDH12 coding variants, namely the p.Arg234His hypomorphic missense<sup>90,103,104</sup> and the 622 623 p.Cys245 Leu247del in-frame variants. The identified c.-123C>T 5'UTR variant was found in cis with p.Arg234His, both in this case as well as in 10 additional RDH12 bi-allelic patients 624 625 screened for this 5'UTR variant, with one of them being homozygous for this complex allele. The pathogenicity of p.Arg234His has been questioned in view of functional assays revealing 626 RDH12 protein levels and catalytic activity comparable to the wild-type or polymorphic alleles, 627 628 respectively<sup>105</sup>. We therefore hypothesized a pathogenic effect exerted by the *RDH12*:c.-629 123C>T variant as part of this complex allele. This 5'UTR variant was predicted to introduce an upstream start codon (uAUG) into a strong Kozak consensus, thereby creating an uORF. Given 630 that ribosomes would first encounter and start translating from this gained uAUG, we 631 632 hypothesized that this variant would decrease normal RDH12 translation and thus result in lower protein levels. Furthermore, this variant has been argued to affect the function of an 633 634 alternative promoter of RDH12 based on the observed decreased activity in a luciferase 635 reporter assay<sup>52</sup>. Importantly, this experimental setup did not include comparison between 636 mRNA levels and luciferase protein activity and was therefore unable to pinpoint at which level the effect occurs. Here, using a dual luciferase assay with the 5'UTR instead of the 637 638 genomic sequence, followed by downstream evaluation at both the mRNA and protein level, 639 we confirmed the hypothesized uORF-mediated effect. We tested this hypothesis further 640 using an overexpression setting and demonstrated unaltered mRNA but significantly reduced 641 RDH12 protein levels, hence confirming the translational effect of *RDH12*:c.-123C>T variant.

Although we could not obtain experimental evidence supporting the translation of the uORFencoded peptide, which might suggest its instability, we cannot rule out alternative mechanisms such as ribosome stalling<sup>9</sup>. However, further studies are needed to confirm this hypothesis. Overall, our results indicate that not p.Arg234His alone, but rather the combination of p.Arg234His and c.-123C>T, or even c.-123C>T by itself, is disease-causing (**Figure 5**).

### 648 **Conclusions**

649 5'UTRs are essential modulators of post-transcriptional and translational control. Even though they can be captured by WES to a large extent, variants within these regions are typically 650 overlooked in both research and routine clinical settings, mainly due to their challenging 651 652 interpretation. In this study, we developed a systematic strategy to comprehensively annotate and prioritize 5'UTR variants in IRD genes. This strategy combined with functional studies 653 654 allowed us to pinpoint 5'UTR variants providing either novel molecular diagnoses or the full 655 picture explaining the pathogenicity of previously reported hypomorphic variants. Overall, in this study we highlight the importance of multi-layered annotation and validation of non-656 657 coding variation potentially underlying disease and provide a 5'UTR interpretation approach that could be extrapolated to other rare diseases. 658

659

660

661

### 663 Abbreviations

- 664 5'UTR: 5' untranslated region
- 665 AD: Autosomal dominant
- 666 AR: Autosomal recessive
- 667 CAGE-seq: Cap analysis gene expression sequencing
- 668 CMGG: Center for Medical Genetics Ghent
- 669 CDS: Coding sequence
- 670 DMEM: Dulbecco's minimal essential medium
- 671 ERDC: European Retinal Disease Consortium
- 672 FC: Fold change
- 673 GE: Genomics England
- 674 IRD: Inherited retinal disease
- 675 IRES : Internal ribosomal entry sites
- 676 MAF: Minor allele frequency
- 677 OD/OS: Oculus dexter/sinister (right/left eye)
- 678 qPCR: Quantitative polymerase chain reaction
- 679 SNV: Single-nucleotide variant
- 680 SV: Structural variant
- 681 TSS : Transcription start site
- 682 TPM: Transcripts per million
- 683 TE: Translational efficiency
- 684 uORF: Upstream open reading frame
- 685 VUS: Variant of uncertain significance
- 686 WES/WGS: Whole exome/genome sequencing



688 Figure 1. Functional annotation of 5'UTR variants, filtering, and prioritization strategy followed in this study. A combination of in silico tools (see Methods) was used to annotate 5'UTR variants, which 689 690 were then classified into 7 functional categories. For each of these categories, specific criteria were 691 established for prioritizing variants with a more likely functional impact (bottom). Only variants with a 692 minor allele frequency (MAF) <2% were further studied. The following information was then reviewed: 693 inheritance pattern of the family (AR including sporadic cases; AD; XL) and clinical features. For the 694 selection of candidate variants, both had to be in agreement with the reported mode of inheritance 695 and phenotype associated with the gene in which the 5'UTR variant was found. Abbreviations: AD: 696 autosomal dominant; AR: autosomal recessive; FC: fold change; IRES: internal ribosomal entry site; TE: 697 translational efficiency; TSS: transcription start site; uAUG: upstream AUG; uORF: upstream open 698 reading frame.

699

700



Figure 2. Characterization of 5'UTRs of IRD genes. (A) Representation of the proportion of IRD gene
isoforms based on the structure of their 5'UTRs. (B) Classification of IRD genes with a retina-enriched
isoform differing to the canonical one based on the comparison of their respective 5'UTRs.



Figure 3. Evaluation of 5'UTR capture by whole-exome sequencing (WES). (A) Boxplots showing the capture performance (*x-axis*) of commonly used commercial exome capture designs on the selected 5'UTRs. The kits that were mostly used for the generation of our in-house WES data are highlighted in *darker gray*. (B) Histogram representing the portions of 5'UTRs (*y-axis*) of the selected IRD genes which are captured by the SureSelect Human All Exon V6 kit (Agilent Technologies) considering a *strict* or a *padded* design (*see Methods*).



Figure 4. Functional evaluation of candidate pathogenic 5'UTR variants in the ARL3, MERTK, PAX6, and RDH12 genes. (A) Various approaches were used for functionally evaluating candidate variants, including *in vitro* studies (dual luciferase reporter assays and overexpression) and experiments with clinically-accessible tissues (expression analysis in patient-derived lymphocytes). (B) Results from the luciferase assays for the *MERTK*:c.-125G>A, *PAX6*:c.-44C>T, and *RDH12*:c.-123C>T variants. The bar

720 plot shows, for each variant, the fold change (FC) of the luciferase reporter level relative to the level 721 of their corresponding wild-type (WT) construct luciferase vector (FC= 1). The RDH12:c.-123C>T and 722 MERTK: c.-125G>A variants resulted in significant (p<0.001) decrease in luciferase activity (~92% and 723 ~99%, respectively). (C) Relative Renilla luciferase mRNA levels were significantly decreased (~42%, 724 p<0.01) for the MERTK:c.-125G>A variant while they remain the same for the RDH12:c.-123C>T variant 725 when normalized to mRNA of Firefly luciferase and compared to their corresponding wild-type (WT) 726 construct luciferase vectors. (D) qPCR quantification of ARL3 mRNA abundance in lymphocyte cDNA of 727 two affected siblings carrying the ARL3:c.-88G>A novel variant and five healthy controls. No significant 728 differences were observed in ARL3 mRNA abundance between the affected carriers and controls. (E-F) Using an overexpression setting, the RDH12:c.-123C>T variant was shown to result in (E) unaltered 729 730 mRNA levels but (F) significantly reduced (~73%, p<0.01) RDH12 protein levels.



731

Figure 5. Proposed pathogenetic mechanism of the *RDH12*: c.[-123C>T];[701G>A] complex allele. 732 733 Graphical representation of the RDH12 wild-type allele (top) and the RDH12 complex allele harboring 734 the c.701G>A (p.Arg234His) and the c.-123C>T variants (bottom). The 5'UTR variant introduces an 735 upstream start codon into a strong Kozak sequence which can be recognized by ribosomes. Either 736 initiation or active translation of the introduced upstream open reading frame (uORF) results in lower 737 translational efficiency of the primary open reading frame (pORF). As a result, there is a decreased 738 level of RDH12 protein with the arginine-to-histidine amino acid substitution at position 734 (blue 739 point).



740

741 Figure S1. Schematic overview of constructs used for functional studies. (A) The wild-type (WT) 742 5'UTRs of the MERTK, PAX6, and RDH12 genes were cloned in-frame into a psiCHECK<sup>M</sup>-2 dual luciferase 743 vector (Promega), containing the Renilla and Firefly luciferase reporter genes under the regulation of the SV40 and HSV-TK promoters, respectively. (B). Depiction of the overexpression RDH12 construct 744 745 comprising the 5'UTR and primary open reading frame (pORF) of RDH12, for which Myc and FLAG in-746 frame tags were included downstream, respectively. This fragment was cloned into a pcDNA<sup>™</sup>3.1<sup>(+)</sup> (Invitrogen) vector downstream its T7 promoter. For all constructs, 5'UTRs variants were created by 747 748 site-directed mutagenesis to obtain mutant (MT) constructs with the variants of interest.

![](_page_34_Figure_4.jpeg)

749

Figure S2. Assessment of transcription start site (TSS) confidence by CAGE-seq in retina.
 Representation of the proportion of IRD gene isoforms based on the support of their annotated TSS
 provided by CAGE-seq data derived from adult and fetal retina.

![](_page_35_Figure_1.jpeg)

Figure S3. Retina-enriched non-canonical isoforms of the *CRB1* and *RIMS2* genes. The shorter alternative isoforms of (A) *CRB1* (ENST00000681519) and (B) *RIMS2* (ENST00000436393) contain 5'UTRs which are completely distinct to those of their respective canonical isoforms

(ENST00000367400.8 and ENST00000696799.1, respectively). The transcription start sites (supported by CAGE-seq) of each canonical and non-canonical isoform (indicated by arrows) are highlighted in *yellow* and *blue*, respectively. Active retinal transcription is supported by bulk RNA-seq and Nuc-seq derived from human retina. The enrichment in retina of these isoforms is further supported by signatures of open chromatin, H3K4me2, and binding of the retina-specific transcription factor CRX (datasets used are listed in **Table S2**).

![](_page_36_Figure_2.jpeg)

![](_page_36_Figure_3.jpeg)

765

766 Figure S4. Evaluation of 5'UTR capture by the kits mostly used for generating our in-house WES data.

767 Comparison of the capture performance of the SureSelect Human All Exon V6 and V7 kits (Agilent

768 Technologies) considering *strict* or *padded* designs (*see Methods*).

769

770

771

![](_page_37_Figure_1.jpeg)

Figure S5. Pedigrees of families carrying the 11 candidate 5'UTR variants and segregation analysis.
(J) Upon clinical re-evaluation, the sibling of F10 (*gray*) was found to be affected by an acquired
vascular ocular condition instead of an IRD. Abbreviations: WT, wild-type allele; M, mutated allele.

![](_page_38_Figure_1.jpeg)

![](_page_38_Figure_2.jpeg)

Figure S6. Secondary structure prediction for wild-type and mutated 5'UTR sequences. Secondary
structure analysis of the 5'UTR sequences (*Ufold* using default parameters) revealed different folding
for the (A) *ARL3*:c.-88G>A, (B) *MERTK*:c.-125G>A, (C) *PAX6*:c.-44T>C, (D) *RD3*:c.-394G>A variants in
comparison to their corresponding wild-type 5'UTRs.

![](_page_38_Figure_4.jpeg)

Figure S7. Kozak consensus sequence of all IRD gene isoforms evaluated in this study. The nucleotides
within the -1 to -10 positions relative to the main AUG were retrieved for all selected transcripts.
Frequency plots corresponding to the Kozak sequences of the (A) retina-enriched (373) and (B) not
retina-enriched canonical transcripts (76).

### 787 Tables

788	Table 2. Summarized overview of the 5'UTR variants that were prioritized as candidates.
789	Abbreviations: AD, autosomal dominant; AR, autosomal recessive; CMGG, Center for Medical
790	Genetics Ghent; GE, Genomics England; LCA, Leber Congenital Amaurosis; MAF, minor allele
791	frequency; TSS, transcription start site; uORF, upstream open reading frame.
792	
793	Additional files
794	Additional file 1 - Supplementary Tables.
795	Table S1. Custom diagnostic gene panel comprising all IRD genes listed in either the Retinal
796	disorders panel (v2.195) from Genomics England PanelApp or RetNet. Abbreviations: AD,
797	autosomal dominant; AR, autosomal recessive; HGNC, HUGO Gene Nomenclature Committee.
798	<b>Table S2</b> . Publicly available multi-omics datasets derived from human retina used in this study.
799	Table S3. Overview of the IRD sub-cohort from the Rare Disease arm of the 100,000 Genomes
800	Project (Genomics England).
801	Table S4. Primer sequences used in this study.
802	Table S5. Overview of selected canonical and non-canonical protein-coding transcripts of IRD
803	genes and their expression in adult human retina. Abbreviations: MANE, Matched Annotation
804	from NCBI and EMBL-EBI; SD, standard deviation; TPM, transcripts per million; TSS,
805	transcription start site.
806	Table S6. Genomic coordinates (GRCh38) of the regions in which variants were searched in
807	this study (5'UTR analysis file).
808	<b>Table S7</b> . Overview of the structure of 5'UTRs of the transcripts included in this study.

Table S8. Comparison of 5'UTRs of non-canonical transcripts with respect to their
 corresponding canonical isoforms.

**Table S9**. Overview of the performance of commercial exome capture designs on the 5'UTRs

812 screened in this study.

**Table S10**. Overview of the performance of commercial exome capture kits mostly used for

the generation of our in-house WES data considering strict and padded designs.

Table S11. Overview of all 5'UTR variants reported in IRD genes submitted to the ClinVardatabase.

Table S12. Overview of the span of internal ribosomal entry sites (IRES) contained in the 5'UTR
of IRD genes.

Table S13. Illustration of the designed prioritization strategy applied to a selection of the
identified variants. Variants which did not pass all criteria (*strikethrough*) were not prioritized
as candidates (*bold*).

Table S14. Overview of additional variants reported for patients F5, F8, F11. Abbreviations:
ACMG, American College of Medical Genetics and Genomics; MAF, minor allele frequency.
Table S15. Overview of the 11 patients carrying the *RDH12*:c.701G>A (p.Arg234His) variant
found *in cis* with *RDH12*:c.-123C>T. Abbreviations: ARG: Argentina; CMGG, Center for Medical
Genetics Ghent; GE, Genomics England; HU FJD: Hospital Universitario Fundación Jiménez
Díaz; IOB: Institute of Molecular and Clinical Ophthalmology Basel; MEH: Moorfields Eye
Hospital.

Additional file 2 - Dataset S1. Annotation of the 1,450 5'UTRs variants that remained after functional classification and filtering. For each cohort (GE or CMGG) there is one tab per functional category.

832

### 833 **Declarations**

#### 834 Ethics approval and consent to participate

- 835 The 100,000 Genomes Project Protocol has ethical approval from the HRA Committee East of
- 836 England Cambridge South (REC Ref 14/EE/1112). This study was registered with Genomics
- 837 England within the *Hearing and sight domain* under Research Registry Projects 465. This study
- was approved by the ethics committee for Ghent University Hospital (B6702021000312) and
- 839 performed in accordance with the tenets of the Helsinki Declaration and subsequent reviews.
- 840 **Consent for publication**
- 841 Not applicable. We present only de-identified data.

### 842 Availability of data and materials

843 The data that support the findings of this study are available within the Genomics England 844 (protected) Research Environment but restrictions apply to the availability of these data, as 845 access to the Research Environment is limited to protect the privacy and confidentiality of participants. Likewise, healthcare and genomic data derived from individuals included in the 846 Center for Medical Genetics Ghent (CMGG) cohort are not publicly available to comply with 847 848 the consent given by those participants. De-identified data as well as analysis scripts are 849 available from the authors upon reasonable request. Extended data generated in this study are available in the supplementary materials. 850

### 851 Competing interests

- 852 The authors declare that they have no competing interests.
- 853 Funding

This work was supported by the Ghent University Special Research Fund (BOF20/GOA/023; BOF/STA/201909/016) (EDB, BPL, FCP); H2020 Marie Sklodowska-Curie Innovative Training Networks (ITN) StarT (grant No. 813490) (ADR, EDB, FC); Ghent University Hospital under the

NucleUZ Grant (EDB, FC); Foundation Fighting Blindness (TA-GT-0621-0810-UGENT) (FCP);
EJPRD19-234 Solve-RET (EDB); Fundación Alfonso Martin Escudero (MDPV); Instituto de Salud
Carlos III (ISCIII) of the Spanish Ministry of Health (CA; FIS: PI22/00321); University Chair UAMIIS-FJD of Genomic Medicine (CA). GA is funded by a Fight For Sight UK Early Career
Investigator Award (5045/46), National Institute of Health Research Biomedical Research
Centre (NIHR-BRC) at Moorfields Eye Hospital and UCL Institute of Ophthalmology and NIHRBRC at Great Ormond Street Hospital Institute for Child Health.

### 864 Authors' contributions

- ADR: Conception and project design, acquisition of data, analysis and interpretation of data,
- 866 drafting and revising the manuscript.
- 867 MDPV: Acquisition of data, analysis and interpretation of data, drafting and revising the 868 manuscript.
- 869 MB: Acquisition of data, analysis and interpretation of data, revising the manuscript.
- 870 FVB: Acquisition of data, revising the manuscript.
- 871 MDV: Acquisition of data, revising the manuscript.
- 872 MVH: Acquisition of data, revising the manuscript.
- 873 MDB: Acquisition of data, revising the manuscript.
- 874 SVS: Acquisition of data, revising the manuscript.
- 875 MBW: Acquisition of data, revising the manuscript.
- 376 JE: Acquisition of data, revising the manuscript.
- 877 GER: Acquisition of data, revising the manuscript.
- 878 CR: Acquisition of data, revising the manuscript.
- 879 AW: Acquisition of data, revising the manuscript.
- GA: Acquisition of data, revising the manuscript.

- 881 CA: Acquisition of data, revising the manuscript.
- 382 JDZ: Acquisition of data, revising the manuscript.
- 883 BL: Acquisition of data, revising the manuscript.
- 884 EDB: Project supervision, acquisition of data, revising the manuscript.
- 885 FC: Conception and project supervision, acquisition of data, analysis and interpretation of
- 886 data, revising the manuscript.

### 887 Acknowledgements

888 This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England 889 Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 890 891 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded 892 893 research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. We thank Olga Zurita 894 895 for their excellent technical assistance. We are grateful to Dr. Jacqueline Cook and Dr. Savita Madhusudhan for their clinical input. 896

897

898

899

900

901

### 903 References

- 9041.Jackson RJ, Hellen CUT, Pestova T V. THE MECHANISM OF EUKARYOTIC TRANSLATION905INITIATION AND PRINCIPLES OF ITS REGULATION. doi:10.1038/nrm2838
- Araujo PR, Yoon K, Ko D, et al. Before It Gets Started: Regulating Translation at the 5' UTR.
   *Comp Funct Genomics*. 2012;2012. doi:10.1155/2012/475731
- 9083.Kozak M. Influences of mRNA secondary structure on initiation by eukaryotic ribosomes. Proc909Natl Acad Sci U S A. 1986;83(9):2850-2854. doi:10.1073/PNAS.83.9.2850
- 9104.Sonenberg N, Hinnebusch AG. Regulation of Translation Initiation in Eukaryotes: Mechanisms911and Biological Targets. *Cell*. 2009;136(4):731. doi:10.1016/J.CELL.2009.01.042
- S. Calvo SE, Pagliarini DJ, Mootha VK. Upstream open reading frames cause widespread
   reduction of protein expression and are polymorphic among humans. *Proc Natl Acad Sci U S* A. 2009;106(18):7507. doi:10.1073/PNAS.0810916106
- Leppek K, Das R, Barna M. Functional 5' UTR mRNA structures in eukaryotic translation
   regulation and how to find them HHS Public Access. *Nat Rev Mol Cell Biol*. 2018;19(3):158 174. doi:10.1038/nrm.2017.103
- 918 7. Bugaut A, Balasubramanian S. 5'-UTR RNA G-quadruplexes: translation regulation and
  919 targeting. doi:10.1093/nar/gks068
- 9208.Steri M, Idda ML, Whalen MB, Orrù V. Genetic Variants in mRNA Untranslated Regions. Wiley921Interdiscip Rev RNA. 2018;9(4):e1474. doi:10.1002/WRNA.1474
- Barbosa C, Peixeiro I, Romão L. Gene Expression Regulation by Upstream Open Reading
   Frames and Human Disease. *PLOS Genet*. 2013;9(8):e1003529.
   doi:10.1371/JOURNAL.PGEN.1003529
- Soukarieh O, Meguerditchian C, Proust C, et al. Common and Rare 5'UTR Variants Altering
   Upstream Open Reading Frames in Cardiovascular Genomics. *Front Cardiovasc Med*.
   2022;9:542. doi:10.3389/FCVM.2022.841032/BIBTEX
- 928 11. Whiffin N, Karczewski KJ, Zhang X, et al. Characterising the loss-of-function impact of 5'
  929 untranslated region variants in 15,708 individuals. *Nat Commun 2020 111*. 2020;11(1):1-12.
  930 doi:10.1038/s41467-019-10717-9
- Smedley D, Smith KR, Martin A, et al. 100,000 Genomes Pilot on Rare-Disease Diagnosis in
   Health Care Preliminary Report. *N Engl J Med*. 2021;385(20):1868-1880.
   doi:10.1056/nejmoa2035790
- Wright CF, FitzPatrick DR, Firth H V. Paediatric genomics: diagnosing rare disease in children.
   *Nat Rev Genet 2018* 195. 2018;19(5):253-268. doi:10.1038/nrg.2017.116
- Fernández-Marmiesse A, Gouveia S, Couce ML. NGS Technologies as a Turning Point in Rare
   Disease Research, Diagnosis and Treatment. *Curr Med Chem*. 2018;25(3):404.
   doi:10.2174/0929867324666170718101946
- Carss K, Arno G, Erwood M, et al. Comprehensive Rare Variant Analysis via Whole-Genome
   Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. *Am J Hum Genet*. 2017;100(1):75-90. doi:10.1016/J.AJHG.2016.12.003
- 94216.Retterer K, Juusola J, Cho MT, et al. Clinical application of whole-exome sequencing across943clinical indications. *Genet Med 2016 187*. 2015;18(7):696-704. doi:10.1038/gim.2015.148

- 17. Lionel AC, Costain G, Monfared N, et al. Improved diagnostic yield compared with targeted
  gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic
  test. *Genet Med*. 2018;20(4):435-443. doi:10.1038/GIM.2017.119
- 947 18. Dai P, Honda A, Ewans L, et al. Recommendations for next generation sequencing data
  948 reanalysis of unsolved cases with suspected Mendelian disorders: A systematic review and
  949 meta-analysis. *Genet Med*. 2022;24(8):1618-1629. doi:10.1016/J.GIM.2022.04.021
- 950 19. Wright CF, Quaife NM, Ramos-Hernández L, et al. Non-coding region variants upstream of
   951 MEF2C cause severe developmental disorder through three distinct loss-of-function
   952 mechanisms. *Am J Hum Genet*. 2021;108(6):1083. doi:10.1016/J.AJHG.2021.04.025
- Zhang X, Wakeling M, Ware J, Whiffin N. Annotating high-impact 5'untranslated region
   variants with the UTRannotator. *Bioinformatics*. 2021;37(8):1171-1173.
   doi:10.1093/BIOINFORMATICS/BTAA783
- 95621.Wang J, Gribskov M. IRESpy: An XGBoost model for prediction of internal ribosome entry957sites. BMC Bioinformatics. 2019;20(1):1-15. doi:10.1186/S12859-019-2999-7/FIGURES/10
- 22. Chatterjee S, Pal JK. Role of 5'- and 3'-untranslated regions of mRNAs in human diseases. *Biol* 259 *Cell*. 2009;101(5):251-262. doi:10.1042/BC20080104
- Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing from
   Primary Sequence with Deep Learning. *Cell*. 2019;176(3):535-548.e24.
   doi:10.1016/J.CELL.2018.12.015
- 24. Zhao J, Wu J, Xu T, Yang Q, He J, Song X. IRESfinder: Identifying RNA internal ribosome entry
  site in eukaryotic cell using framed k-mer features. *J Genet Genomics*. 2018;45(7):403-406.
  doi:10.1016/J.JGG.2018.07.006
- 25. Lim Y, Arora S, Schuster SL, et al. Multiplexed functional genomic analysis of 5' untranslated
  region mutations across the spectrum of prostate cancer. *Nat Commun 2021 121*.
  2021;12(1):1-18. doi:10.1038/s41467-021-24445-6
- 969 26. Filatova A, Reveguk I, Piatkova M, et al. Annotation of uORFs in the OMIM genes allows to
  970 reveal pathogenic variants in 5'UTRs. *Nucleic Acids Res.* 2023;51(3):1229-1244.
  971 doi:10.1093/nar/gkac1247
- 972 27. Ellingford JM, Ahn JW, Bagnall RD, et al. Recommendations for clinical interpretation of
  973 variants found in non-coding regions of the genome. *Genome Med*. 2022;14(1):1-19.
  974 doi:10.1186/S13073-022-01073-3/FIGURES/3
- 975 28. Pontikos N, Arno G, Jurkute N, et al. Genetic Basis of Inherited Retinal Disease in a Molecularly
  976 Characterized Cohort of More Than 3000 Families from the United Kingdom. Published online
  977 2020. doi:10.1016/j.ophtha.2020.04.008
- 829. Ratnapriya R, Swaroop A. Genetic architecture of retinal and macular degenerative diseases:
  by the promise and challenges of next-generation sequencing. *Genome Med.* 2013;5(10).
  by doi:10.1186/GM488
- 981 30. O'sullivan J, Mullaney BG, Bhaskar SS, et al. A paradigm shift in the delivery of services for
   982 diagnosis of inherited retinal disease. doi:10.1136/jmedgenet-2012-100847
- 983 31. Dockery A, Whelan L, Humphries P, Farrar GJ, Malerba G. Next-Generation Sequencing
   984 Applications for Inherited Retinal Diseases. Published online 2021. doi:10.3390/ijms22115684
- 98532.Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and986vitreoretinal diseases. *Prog Retin Eye Res.* 2010;29(5):335-375.

### 987 doi:10.1016/J.PRETEYERES.2010.03.004

- Hanany M, Rivolta C, Sharon D. Worldwide carrier frequency and genetic prevalence of
  autosomal recessive inherited retinal diseases. *Proc Natl Acad Sci U S A*. 2020;117(5):27102716. doi:10.1073/PNAS.1913179117
- 991 34. RetNet Retinal Information Network. Accessed April 6, 2023.
  992 https://web.sph.uth.edu/RetNet/
- 99335.Tatour Y, Ben-Yosef T. Syndromic Inherited Retinal Diseases: Genetic, Clinical and Diagnostic994Aspects. Diagnostics (Basel, Switzerland). 2020;10(10). doi:10.3390/DIAGNOSTICS10100779
- 995 36. Ellingford JM, Hufnagel RB, Arno G. Phenotype and Genotype Correlations in Inherited Retinal
   996 Diseases: Population-Guided Variant Interpretation, Variable Expressivity and Incomplete
   997 Penetrance. *Genes (Basel)*. 2020;11(11):1-4. doi:10.3390/GENES1111274
- 998 37. Sharon D, Ben-Yosef T, Goldenberg-Cohen N, et al. A nationwide genetic analysis of inherited
  999 retinal diseases in Israel as assessed by the Israeli inherited retinal disease consortium (IIRDC).
  1000 *Hum Mutat*. 2020;41(1):140-149. doi:10.1002/HUMU.23903
- 1001 38. Perea-Romero I, Gordo G, Iancu IF, et al. Genetic landscape of 6089 inherited retinal
   1002 dystrophies affected cases in Spain and their therapeutic and extended epidemiological
   1003 implications. *Sci Rep.* 2021;11(1). doi:10.1038/S41598-021-81093-Y
- Fadaie Z, Whelan L, Ben-Yosef T, et al. Whole genome sequencing and in vitro splice assays
  reveal genetic causes for inherited retinal diseases. *NPJ genomic Med*. 2021;6(1).
  doi:10.1038/S41525-021-00261-1
- 100740.Lenassi E, Clayton-Smith J, Douzgou S, et al. Clinical utility of genetic testing in 201 preschool1008children with inherited eye disorders. *Genet Med.* 2020;22(4):745-751. doi:10.1038/S41436-1009019-0722-8
- 1010 41. Lam BL, Leroy BP, Black G, Ong T, Yoon D, Trzupek K. Genetic testing and diagnosis of
  1011 inherited retinal diseases. *Orphanet J Rare Dis*. 2021;16(1):1-9. doi:10.1186/S13023-0211012 02145-0/TABLES/2
- 1013 42. Liquori A, Vaché C, Baux D, et al. Whole USH2A Gene Sequencing Identifies Several New Deep
  1014 Intronic Mutations. *Hum Mutat*. 2016;37(2):184-193. doi:10.1002/HUMU.22926
- Holtan JP, Selmer KK, Heimdal KR, Bragadóttir R. Inherited retinal disease in Norway a
  characterization of current clinical and genetic knowledge. *Acta Ophthalmol*. 2020;98(3):286295. doi:10.1111/AOS.14218
- 101844.Reurink J, Weisschuh N, Garanto A, et al. Whole genome sequencing for USH2A-associated1019disease reveals several pathogenic deep-intronic variants that are amenable to splice1020correction. HGG Adv. 2023;4(2). doi:10.1016/J.XHGG.2023.100181
- Hauwens M, Garanto A, Sangermano R, et al. ABCA4-associated disease as a model for missing heritability in autosomal recessive disorders: novel noncoding splice, cis-regulatory, structural, and recurrent hypomorphic variants. *Genet Med*. 2019;21(8):1761-1771.
  doi:10.1038/S41436-018-0420-Y
- 102546.Sangermano R, Garanto A, Khan M, et al. Deep-intronic ABCA4 variants explain missing1026heritability in Stargardt disease and allow correction of splice defects by antisense1027oligonucleotides. Genet Med. 2019;21(8):1751-1760. doi:10.1038/S41436-018-0414-9
- Khan M, Cornelis SS, Pozo-Valero M Del, et al. Resolving the dark matter of ABCA4 for 1054
  Stargardt disease probands through integrated genomics and transcriptomics. *Genet Med*.

### 1030 2020;22(7):1235-1246. doi:10.1038/S41436-020-0787-4

- 1031 48. Daich Varela M, Bellingham J, Motta F, et al. Multidisciplinary team directed analysis of whole
  1032 genome sequencing reveals pathogenic non-coding variants in molecularly undiagnosed
  1033 inherited retinal dystrophies. *Hum Mol Genet*. 2023;32(4):595-607.
  1034 doi:10.1093/HMG/DDAC227
- 1035 49. Qian X, Wang J, Wang M, et al. Identification of Deep-Intronic Splice Mutations in a Large
  1036 Cohort of Patients With Inherited Retinal Diseases. *Front Genet*. 2021;12:276.
  1037 doi:10.3389/FGENE.2021.647400/BIBTEX
- 1038 50. Weisschuh N, Sturm M, Baumann B, et al. Deep-intronic variants in CNGB3 cause
  1039 achromatopsia by pseudoexon activation HHS Public Access. *Hum Mutat*. 2020;41(1):255-264.
  1040 doi:10.1002/humu.23920
- 1041 51. Jamshidi F, Place EM, Mehrotra S, et al. Contribution of noncoding pathogenic variants to
  1042 RPGRIP1-mediated inherited retinal degeneration. *Genet Med.* 2019;21(3):694-704.
  1043 doi:10.1038/S41436-018-0104-7
- 1044 52. Cherry TJ, Yang MG, Harmin DA, et al. Mapping the cis-regulatory architecture of the human
  1045 retina reveals noncoding genetic variation in disease. *Proc Natl Acad Sci U S A*.
  1046 2020;117(16):9001-9012. doi:10.1073/PNAS.1922501117/-/DCSUPPLEMENTAL
- 1047 53. Coppieters F, Todeschini AL, Fujimaki T, et al. Hidden Genetic Variation in LCA9-Associated
  1048 Congenital Blindness Explained by 5'UTR Mutations and Copy-Number Variations of NMNAT1.
  1049 Hum Mutat. 2015;36(12):1188. doi:10.1002/HUMU.22899
- 1050 54. Ruberto FP, Balzano S, Namburi P, et al. Heterozygous deletions of noncoding parts of the
  1051 PRPF31 gene cause retinitis pigmentosa via reduced gene expression. *Mol Vis*. 2021;27:107.
  1052 Accessed April 11, 2023. /pmc/articles/PMC8056469/
- 105355.Van de Sompele S, Small KW, Cicekdal MB, et al. Multi-omics approach dissects cis-regulatory1054mechanisms underlying North Carolina macular dystrophy, a retinal enhanceropathy. Am J1055Hum Genet. 2022;109(11):2029-2048. doi:10.1016/J.AJHG.2022.09.013
- 1056 56. Small KW, DeLuca AP, Whitmore SS, et al. North Carolina Macular Dystrophy is caused by
  1057 dysregulation of the retinaltranscription factor PRDM13. *Ophthalmology*. 2016;123(1):9.
  1058 doi:10.1016/J.OPHTHA.2015.10.006
- 1059 57. Filatova AY, Vasilyeva TA, Marakhonov A V., et al. Upstream ORF frameshift variants in the
  1060 PAX6 5'UTR cause congenital aniridia. *Hum Mutat*. 2021;42(8):1053-1065.
  1061 doi:10.1002/HUMU.24248
- 1062 58. Zuercher J, Neidhardt J, Magyar I, et al. Alterations of the 5'Untranslated Region of SLC16A12
  1063 Lead to Age-Related Cataract. *Invest Ophthalmol Vis Sci*. 2010;51(7):3354.
  1064 doi:10.1167/IOVS.10-5193
- 1065 59. Zhang W, Kassels AC, Barrington A, et al. Macular corneal dystrophy with isolated peripheral
  1066 Descemet membrane deposits. *Am J Ophthalmol Case Reports*. 2019;16.
  1067 doi:10.1016/J.AJOC.2019.100571
- 106860.Ratnapriya R, Sosina OA, Starostik MR, et al. Retinal transcriptome and eQTL analyses identify1069genes associated with age-related macular degeneration. Nat Genet. 2019;51(4):606-610.1070doi:10.1038/S41588-019-0351-9
- Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification.
   *Nat Biotechnol.* 2016;34(5):525-527. doi:10.1038/NBT.3519

1073	62.	Morales J, Pujar S, Loveland JE, et al. A joint NCBI and EMBL-EBI transcript set for clinical
1074		genomics and research. <i>Nature</i> . 2022;604(7905). doi:10.1038/S41586-022-04558-8

- 1075 63. Martin AR, Williams E, Foulger RE, et al. PanelApp crowdsources expert knowledge to
  1076 establish consensus diagnostic gene panels. *Nat Genet*. 2019;51(11):1560-1565.
  1077 doi:10.1038/S41588-019-0528-2
- 107864.Forrest ARR, Kawaji H, Rehli M, et al. A promoter-level mammalian expression atlas. Nature.10792014;507(7493):462-470. doi:10.1038/NATURE13182
- 1080 65. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features.
  1081 *Bioinforma Appl NOTE*. 2010;26(6):841-842. doi:10.1093/bioinformatics/btq033
- 108266.Landrum MJ, Lee JM, Benson M, et al. ClinVar: public archive of interpretations of clinically1083relevant variants. Nucleic Acids Res. 2016;44(D1):D862-D868. doi:10.1093/NAR/GKV1222
- 108467.Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform.10852009;25(14):1754-1760. doi:10.1093/bioinformatics/btp324
- 1086 68. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework
  1087 for analyzing next-generation DNA sequencing data. *Genome Res.* 2010;20(9):1297-1303.
  1088 doi:10.1101/GR.107524.110
- 1089 69. Danecek P, Bonfield JK, Liddle J, et al. Twelve years of SAMtools and BCFtools. *Gigascience*.
  2021;10(2). doi:10.1093/GIGASCIENCE/GIAB008
- 109170.McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. Genome Biol.10922016;17(1). doi:10.1186/S13059-016-0974-4
- 109371.Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from1094variation in 141,456 humans. Nature. 2020;581(7809):434-443. doi:10.1038/S41586-020-10952308-7
- 109672.Jian X, Boerwinkle E, Liu X. In silico prediction of splice-altering single nucleotide variants in1097the human genome. Nucleic Acids Res. 2014;42(22):13534-13544. doi:10.1093/NAR/GKU1206
- Yeo G, Burge CB. Maximum Entropy Modeling of Short Sequence Motifs with Applications to
  RNA Splicing Signals. *https://home.liebertpub.com/cmb*. 2004;11(2-3):377-394.
  doi:10.1089/1066527041410418
- 1101 74. Frazer J, Notin P, Dias M, et al. Disease variant prediction with deep generative models of
  1102 evolutionary data. *Nat 2021 5997883*. 2021;599(7883):91-95. doi:10.1038/s41586-021-040431103 8
- 1104 75. Kircher M, Witten DM, Jain P, O'roak BJ, Cooper GM, Shendure J. A general framework for
  1105 estimating the relative pathogenicity of human genetic variants. *Nat Genet*. 2014;46(3):3101106 315. doi:10.1038/NG.2892
- 1107 76. Zerbino DR, Wilder SP, Johnson N, Juettemann T, Flicek PR. The ensembl regulatory build.
  1108 *Genome Biol*. 2015;16(1):56-56. doi:10.1186/S13059-015-0621-5
- 1109 77. Kozak M. The scanning model for translation: an update. *J Cell Biol*. 1989;108(2):229-241.
   1110 doi:10.1083/JCB.108.2.229
- 1111 78. McClements ME, Butt A, Piotter E, Peddle CF, Maclaren RE. An analysis of the Kozak
  1112 consensus in retinal genes and its relevance to gene therapy. *Mol Vis*. 2021;27:233. Accessed
  1113 March 15, 2023. /pmc/articles/PMC8116250/
- 1114 79. Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: a sequence logo generator. *Genome*

### 1115 Res. 2004;14(6):1188-1190. doi:10.1101/GR.849004

- 1116 80. Sample PJ, Wang B, Reid DW, et al. Human 5' UTR design and variant effect prediction from a
  1117 massively parallel translation assay. *Nat Biotechnol 2019 377*. 2019;37(7):803-809.
  1118 doi:10.1038/s41587-019-0164-5
- 1119 81. Murat P, Marsico G, Herdy B, Ghanbarian A, Portella G, Balasubramanian S. RNA G1120 quadruplexes at upstream open reading frames cause DHX36- and DHX9-dependent
  1121 translation of human mRNAs. *Genome Biol.* 2018;19(1):1-24. doi:10.1186/S13059-018-16021122 2/FIGURES/6
- 1123 82. Li H. Tabix: fast retrieval of sequence features from generic TAB-delimited files.
  1124 *Bioinformatics*. 2011;27(5):718. doi:10.1093/BIOINFORMATICS/BTQ671
- 112583.Fu L, Cao Y, Wu J, Peng Q, Nie Q, Xie X. UFold: fast and accurate RNA secondary structure1126prediction with deep learning. Nucleic Acids Res. 2022;50(3):e14-e14.1127doi:10.1093/NAR/GKAB1074
- 112884.Chen CC, Chan YM. REDfold: accurate RNA secondary structure prediction using residual1129encoder-decoder network. *BMC Bioinformatics*. 2023;24(1):122. doi:10.1186/S12859-023-113005238-8/FIGURES/3
- 1131 85. Sato K, Akiyama M, Sakakibara Y. RNA secondary structure prediction using deep learning
  1132 with thermodynamic integration. *Nat Commun 2021 121*. 2021;12(1):1-9.
  1133 doi:10.1038/s41467-021-21194-4
- 1134 86. Yang TH, Wang CY, Tsai HC, Liu CT. Human IRES Atlas: an integrative platform for studying
  1135 IRES-driven translational regulation in humans. *Database*. 2021;2021:1-16.
  1136 doi:10.1093/DATABASE/BAAB025
- 113787.Bates D, Mächler M, Bolker BM, Walker SC. Fitting Linear Mixed-Effects Models Using Ime4. J1138Stat Softw. 2015;67(1):1-48. doi:10.18637/JSS.V067.I01
- 1139 88. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative
  1140 quantification framework and software for management and automated analysis of real-time
  1141 quantitative PCR data. Published online 2007. doi:10.1186/gb-2007-8-2-r19
- 114289.Dryja TP, McGee TL, Berson EL, et al. Night blindness and abnormal cone electroretinogram1143ON responses in patients with mutations in the GRM6 gene encoding mGluR6. Proc Natl Acad1144Sci U S A. 2005;102(13). doi:10.1073/pnas.0501233102
- 114590.De Zaeytijd J, Van Cauwenbergh C, De Bruyne M, et al. ISOLATED MACULOPATHY AND1146MODERATE ROD-CONE DYSTROPHY REPRESENT THE MILDER END OF THE RDH12-RELATED1147RETINAL DYSTROPHY SPECTRUM. *Retina*. 2021;41(6):1346-1355.1148doi:10.1097/IAE.00000000003028
- 1149 91. Tiering (Rare Disease) Genomics England Research Environment Genomics England
  1150 Confluence. Accessed April 14, 2023.
  1151 https://cnfl.extge.co.uk/pages/viewpage.action?pageId=113194832
- Schmitz-Abe K, Li Q, Rosen SM, et al. Unique bioinformatic approach and comprehensive reanalysis improve diagnostic yield of clinical exomes. *Eur J Hum Genet 2019 279*.
  2019;27(9):1398-1405. doi:10.1038/s41431-019-0401-x
- 1155 93. Wenger AM, Guturu H, Bernstein JA, Bejerano G. Systematic reanalysis of clinical exome data
  1156 yields additional diagnoses: implications for providers. *Genet Med*. 2017;19(2):209-214.
  1157 doi:10.1038/GIM.2016.88

- 115894.de Bruijn SE, Rodenburg K, Corominas J, et al. Optical genome mapping and revisiting short-1159read genome sequencing data reveal previously overlooked structural variants disrupting1160retinal disease-associated genes. Genet Med. 2023;25(3). doi:10.1016/J.GIM.2022.11.013
- 1161 95. Del Pozo-Valero M, Martin-Merida I, Jimenez-Rolando B, et al. Expanded Phenotypic
  1162 Spectrum of Retinopathies Associated with Autosomal Recessive and Dominant Mutations in
  1163 PROM1. Am J Ophthalmol. 2019;207:204-214. doi:10.1016/J.AJO.2019.05.014
- 1164 96. Moreno-Leon L, West EL, O'Hara-Wright M, et al. RPGR isoform imbalance causes ciliary
  1165 defects due to exon ORF15 mutations in X-linked retinitis pigmentosa (XLRP). *Hum Mol Genet*.
  1166 2021;29(22):3706-3716. doi:10.1093/HMG/DDAA269
- 1167 97. Vig A, Poulter JA, Ottaviani D, et al. DYNC2H1 hypomorphic or retina-predominant variants
  1168 cause nonsyndromic retinal degeneration. *Genet Med*. 2020;22(12):2041-2051.
  1169 doi:10.1038/S41436-020-0915-1
- 1170 98. Riazuddin SA, Iqbal M, Wang Y, et al. A splice-site mutation in a retina-specific exon of BBS8
  1171 causes nonsyndromic retinitis pigmentosa. *Am J Hum Genet*. 2010;86(5):805-812.
  1172 doi:10.1016/J.AJHG.2010.04.001
- 1173 99. Mairot K, Smirnov V, Bocquet B, et al. CRB1-Related Retinal Dystrophies in a Cohort of 50
  1174 Patients: A Reappraisal in the Light of Specific Müller Cell and Photoreceptor CRB1 Isoforms.
  1175 Int J Mol Sci. 2021;22(23):12642. doi:10.3390/IJMS222312642
- 100. Weber R, Ghoshdastider U, Spies D, et al. Monitoring the 5'UTR landscape reveals isoform
  switches to drive translational efficiencies in cancer. *Oncogene*. 2023;42(9):638-650.
  doi:10.1038/S41388-022-02578-2
- 101. Ray TA, Cochran K, Kozlowski C, et al. Comprehensive identification of mRNA isoforms reveals
  the diversity of neural cell-surface molecules with roles in retinal development and disease. *Nat Commun.* 2020;11(1). doi:10.1038/S41467-020-17009-7
- 1182102.Yu M, Baehr W, Lei B, et al. A Novel ARL3 Gene Mutation Associated With Autosomal1183Dominant Retinal Degeneration. Published online 2021. doi:10.3389/fcell.2021.720782
- 1184103.Wang J, Wang Y, Li S, et al. Clinical and Genetic Analysis of RDH12-Associated Retinopathy in118527 Chinese Families: A Hypomorphic Allele Leads to Cone-Rod Dystrophy. Published online11862022. doi:10.1167/iovs.63.9.24
- 1187 104. Ba-Abbad R, Arno G, Robson AG, et al. Macula-predominant retinopathy associated with
  biallelic variants in RDH12. *Ophthalmic Genet*. 2020;41(6):612-615.
  doi:10.1080/13816810.2020.1802763
- 1190 105. Thompson DA, Janecke AR, Lange J, et al. Retinal degeneration associated with RDH12
  1191 mutations results from decreased 11- cis retinal synthesis due to disruption of the visual cycle.
  1192 Hum Mol Genet. 2005;14(24):3865-3875. doi:10.1093/HMG/DDI411